Strategic partnerships Plus Therapeutics is actively expanding collaborations across CNS oncology through regional coverage agreements, genomic testing partnerships, and AI-driven data platforms, signaling opportunities for channel partnerships, contract research, and co-development pilots.

Clinical-program expansion The company is advancing REYOBIQ within multi-center ReSPECT trials for recurrent glioblastoma and other CNS cancers, highlighting potential for research collaborations, investigator-initiated studies, and early access programs with hospitals and cancer centers.

AI and data capabilities Recent investments in AI platforms and longitudinal data integration across CNS programs present sales opportunities for data analytics services, AI model licensing, and decision-support tools for clinical and translational research teams.

Manufacturing readiness Initiation of late-stage manufacturing and technology transfer with partners indicates a need for scalable supply chain solutions, GMP services, and contract manufacturing support to ensure clinical and potential commercial scale-up.

Financial and market readiness Healthy funding and a modest revenue base position Plus Therapeutics for strategic commercial partnerships, co-marketing arrangements, and value-added diagnostics collaborations with payers and CNS cancer care networks.